Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 18, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details specific transactions involving the GlaxoSmithKline (US) Trust ("GSK US Trust") on October 17, 2005:
- Abacus Corporate Trustee Limited sold 7,038 ADR Shares to participants in the GlaxoSmithKline Restricted Share Plan.
- Abacus Corporate Trustee Limited transferred 14,872 ADR Shares to participants in the GlaxoSmithKline Restricted Share Plan.
These transactions were advised to the Company on October 18, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK US Trust is a grantor trust for employees or former employees of SmithKline Beecham Corporation and its subsidiaries. Two directors, Dr. J-P Garnier and Dr. T Yamada, hold interests in the shares held in the GSK US Trust in the same capacity as other employees.
Investor Verification Points
- Verify the total number of ADR shares distributed to the Restricted Share Plan (21,910 total shares via sale and transfer).
- Confirm the specific roles of Dr. J-P Garnier and Dr. T Yamada regarding their interest in the GSK US Trust.
- Note that this filing does not reflect operational or financial performance for the period.